Immuno-chemotherapy is not a standard treatment for CLL anymore and new targeted agents are recommended in the first line setting such as BTK inhibitors and anti bcl-2 agents [29]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.